glp-1/gip/glucagon receptor agonist GLP1-GIP co-agonists: a promising evolution in the treatment of type 2 diabetes | Acta Diabetologica The mechanism of GLP-1 and

Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology

Newer research suggests that semaglutide may also have a protective effect on the kidneys

Before we discuss these drugs further, a quick reminder that it's always best to seek medical advice from healthcare providers about what may or may not be right for you

The CDSCO has just issued a clear advisory (dated March 11, 2026) directing all manufacturers, importers, and marketing authorization holders of GLP-1 receptor agonists (like semaglutide/Ozempic, tirzepatide/Mounjaro, etc.) to strictly avoid any promotional activities for these prescription-only drugs used in obesity management

74 VadiniF.SimeoneP.BoccatondaA.GuagnanoM.LianiR.TripaldiR.et al (2020)

In AD, along with amyloid and tau phosphorylation, there is an associated increase in inflammation/glial activation, a decrease in synaptic function, an increase in astrocyte activation, and a state of insulin resistance